In stage II a participant in the DAZ–PBO group experienced an SAE of DVT; however, onset occurred 180 days after the last dose of DAZ; by contrast, in previous reports thromboembolic events associated with anti-CD40L mAbs occurred relatively soon after dosing. This evidence concerns the gene CD40LG and deep vein thrombosis.